4.8 • 1.4K Ratings
🗓️ 8 September 2022
⏱️ 16 minutes
🧾️ Download transcript
Click on a timestamp to play from that location
0:00.0 | Behind the Knife, the Surgery Podcast, relevant and engaging content designed to help you |
0:12.0 | dominate the day. |
0:14.0 | Hello, we'd like to welcome you to another episode of Behind the Knife Podcast for |
0:27.6 | surgical oncology. My name is Adam Yoke. I'm one of the surgical oncologists at UT Southwestern |
0:32.2 | in Dallas. I have a pleasure to be joined by two up and coming surgical oncologists, Dr. |
0:39.5 | Gilbert Marimoa, who's a research resident at UT Southwestern in his PGY five year right |
0:48.2 | now. And Dr. Caitlin Hester, who will be a new faculty member at the University of Miami as an |
0:55.4 | associate assistant professor of surgery at the University of Miami, the division of surgical |
1:00.2 | oncologists, so welcome to you both. So today we're going to review the practice changing MSL T2 |
1:07.9 | trial. The multi-center selective lymphatic anatomy trials are quite monumental in the management of |
1:14.1 | how we treat patients and how we care for patients with melanoma. They're really high level and I |
1:20.1 | think everybody will agree high impact research and should serve as an example how clinical trials |
1:25.9 | in the United States with multi-institution should really be conducted. Prior to delving right |
1:31.9 | into the second MSLT trial, I think it's probably important that we really lay the framework |
1:38.8 | by outlining the first MSLT trial. So Caitlin, really what was the aim of the first MSLT trial? |
1:45.2 | This trial really aimed to determine if sentinel node biopsy could be used to identify |
1:50.6 | patients with clinically occult nodal metastases and whether immediate completion lymphadenectomy |
1:57.6 | among those who were who did have positive sentinel lymph nodes yielded improved outcomes compared |
2:04.9 | to nodal observation without sentinel lymph node biopsy. Gilbert, what patient's story is important |
2:11.6 | when we talk about clinical trials about the applicability to the greater population at large |
2:18.1 | and really it's what patients were included in this study and who was excluded more importantly. |
2:25.0 | So any patient with primary and cutaneous melanomas greater than one millimeter in thickness |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Behind The Knife: The Surgery Podcast, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Behind The Knife: The Surgery Podcast and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2025.